Elanco Animal Health vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Elanco Animal Health (ELAN)

Q3 202616 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

August 202616 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

Latest16 Jul – 31 Aug 2026

▲4

Elanco beats Q2, raises guidance, wins FDA nod and expands plant

Q2 beat and raised 2026 guidance Elanco beat second-quarter estimates and raised its full-year 2026 outlook, with revenue up about 10% to $1.37 billion and adjusted EPS of 34 cents. Management lifted revenue, profit and innovation targets, signaling stronger demand for its new pet and farm animal products. Higher expected earnings make the stock more attractive to investors.
This is the core new financial event that directly lifts ELAN's earnings outlook and stock price.
FDA emergency use authorization for CLiK Extra The FDA granted Elanco emergency use authorization for CLiK Extra, a wound spray to prevent new world screwworm in livestock and wildlife. This followed the first U.S. animal case in Texas. The authorization opens a new over-the-counter product line and shows Elanco's ability to respond to emerging animal health threats.
A new regulatory approval creates a fresh revenue opportunity and supports the stock.
Kansas biologics plant expansion completed Elanco finished a $120 million expansion of its Kansas biologics facility, more than quadrupling monoclonal antibody production capacity. The added capacity supports the launch of Befrena for canine allergies and Trutect for parvovirus, with Befrena demand running twice expectations. More supply helps Elanco meet strong demand and grow sales.
This new capacity directly enables higher sales of key new products, supporting future revenue.
Pet anti-aging trend boosts long-term demand The anti-aging trend is spreading to pets, with U.S. pet spending expected to hit a record $165 billion this year. Elanco invested $368 million in pet longevity research last year, positioning it in a growing market. Rising pet owner spending on health and longevity supports demand for Elanco's products over time.
A new market trend that expands the potential customer base and long-term demand for Elanco's pet products.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.